The oral oxazolidinone antibiotic targets infections due to multi-drug resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
MicuRx president and chief executive officer Zhengyu Yuan said the results of the clinical study show that MRX-I may represent the next generation of safer oxazolidinone antibiotics, not offered in the field to date.
"Based on the positive results, we expect to initiate Phase 2 clinical trials in both the United States and China, to determine optimal dosing for MRX-I," Yuan added.
The double-blind study evaluated safety, tolerability and pharmacokinetics of MRX-I, both in a single ascending dosing of up to 1800mg, and in a 15-day multiple-dose regimens of twice-daily 600mg and 800mg.
MRX-I was well tolerated, with no evidence of myelosuppression and was well absorbed, with exposure levels similar to linezolid, the study reported.